{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/bilingual-documentation-expectations”
},
“@id”: “https://www.clinicalstudies.in/bilingual-documentation-expectations”,
“headline”: “SOP for Bilingual Documentation Expectations”,
“name”: “SOP for Bilingual Documentation Expectations”,
“description”: “Detailed SOP for preparing, reviewing, and controlling bilingual (English and French) documents such as ICFs, IBs, safety narratives, and regulatory submissions, aligned with Health Canada and ICH-GCP.”,
“keywords”: “bilingual documentation SOP, translation quality assurance, English French clinical trial documents, informed consent bilingual Canada, bilingual investigator brochures, REB submission requirements, CTA bilingual dossier, translation certification SOP, bilingual patient information sheets, clinical trial bilingual communication, bilingual safety narratives, Health Canada document compliance, sponsor responsibilities bilingual docs, bilingual protocol amendments, bilingual subject materials, bilingual trial forms Canada, translation verification SOP, inspection readiness bilingual documents, bilingual trial governance, REB bilingual reporting, bilingual ICF comprehension, bilingual archiving SOP, bilingual ethics documents, bilingual trial master file, Health Canada bilingual guidance”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}
Published on 26/12/2025
Bilingual Documentation Expectations SOP
| Department | Clinical Research |
|---|---|
| SOP No. | CS/HC-SAF/168/2025 |
| Supersedes | N.A. |
| Page No. | 1 of 20 |
| Issue Date | 28/08/2025 |
| Effective Date | 05/09/2025 |
| Review Date | 05/09/2027 |
Purpose
This SOP defines the processes for preparing, translating, verifying, and controlling bilingual (English and French) documentation used in clinical trials. It ensures compliance with Health Canada Division 5, ICH-GCP, and REB requirements, guaranteeing that participants receive understandable and accurate information while sponsors maintain regulatory compliance and inspection readiness.
Scope
This SOP applies to all sponsor, CRO, and investigator site personnel involved in preparing bilingual documentation for clinical trials. It includes informed consent forms (ICFs), patient information sheets, Investigator’s Brochures (IBs), Clinical Trial Applications (CTAs), safety narratives, regulatory correspondence, and ethics submissions. It covers initial submissions, amendments, safety updates, and final reports.
Responsibilities
- Clinical Research Department: Ensures bilingual documentation is created, reviewed, and filed in the TMF.
- Regulatory Affairs (RA): Confirms CTAs and amendments contain certified English and French versions as required.
- Principal Investigator (PI): Provides bilingual ICFs to participants and ensures comprehension during the consent process.
- Translation Vendor/Language Specialists: Perform certified translations, maintain audit trails, and issue certificates of accuracy.
- Quality Assurance (QA): Audits bilingual documentation processes and verifies compliance with regulatory and ethical requirements.
Accountability
The Head of Clinical Research holds accountability for ensuring bilingual documents meet Health Canada and REB requirements. PIs are accountable for ensuring participants receive understandable bilingual consent materials before trial enrollment.
Procedure
1. Identification of Required Bilingual Documents
- Identify all subject-facing and regulatory documents requiring bilingual versions (ICFs, IBs, patient leaflets, safety updates).
- Maintain a Translation Requirement Log in the TMF.
2. Translation and Verification
- Engage certified translators with medical expertise.
- Perform back-translation of critical subject-facing materials (e.g., ICFs, safety narratives).
- Document discrepancies between forward and back translations and resolve prior to finalization.
3. Quality Review and Certification
- Obtain Certificates of Translation Accuracy from vendors for all finalized translations.
- Regulatory Affairs confirms alignment between English and French versions prior to submission.
- File all certificates and QA reviews in the TMF.
4. Submissions and Approvals
- Include bilingual documents in CTA packages submitted to Health Canada.
- Ensure REB submissions include both English and French ICFs for review.
- Confirm acknowledgment and approval letters are archived in both ISF and TMF.
5. Site-Level Use
- Provide participants with bilingual ICFs at enrollment and confirm understanding using comprehension checklists.
- Ensure bilingual documentation is readily available at sites for inspection.
6. Documentation and Archiving
- Maintain Translation Requirement Logs, Certificates of Translation, and QA verification logs in the TMF.
- Archive bilingual versions of all essential documents for at least 25 years or until marketing authorization is complete.
Abbreviations
- CTA: Clinical Trial Application
- GCP: Good Clinical Practice
- ICF: Informed Consent Form
- IB: Investigator’s Brochure
- QA: Quality Assurance
- REB: Research Ethics Board
- TMF: Trial Master File
Documents
- Translation Requirement Log (Annexure-1)
- Certificate of Translation Accuracy (Annexure-2)
- Bilingual Consent Comprehension Checklist (Annexure-3)
References
- Health Canada — Clinical Trial Guidance
- Food and Drug Regulations, Part C, Division 5
- ICH E6(R2) Good Clinical Practice
- Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans
Version: 1.0
Approval
| Prepared By | Checked By | Approved By |
|---|---|---|
| Name: Rajesh Kumar Date: 20/08/2025 Signature: __________ |
Name: Sunita Reddy Date: 22/08/2025 Signature: __________ |
Name: Dr. Meera Iyer Date: 28/08/2025 Signature: __________ |
Annexures
Annexure-1: Translation Requirement Log
| Date | Document | Language | Translator | Status |
|---|---|---|---|---|
| 05/08/2025 | ICF v1.0 | French | Montreal MedTrans | Completed |
Annexure-2: Certificate of Translation Accuracy
| Document | Translator | Certification Date | Reviewer |
|---|---|---|---|
| ICF v1.0 | Dr. Louise Tremblay | 06/08/2025 | Sunita Reddy |
Annexure-3: Bilingual Consent Comprehension Checklist
| Subject ID | ICF Version | Language Provided | Comprehension Confirmed By | Date |
|---|---|---|---|---|
| SUB-001 | v1.0 | French | PI – Dr. Desai | 10/08/2025 |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 28/08/2025 | 1.0 | Initial SOP for bilingual documentation expectations. | New SOP developed for compliance with Division 5 and ICH-GCP. | Head of Clinical Research |
For more SOPs visit: Pharma SOP.